Observational analysis shows poorer outcomes in DLBCL with high IgM versus IgG1, indicating distinct roles in lymphoma pathology.
Malignant B cells rely on B cell receptor (BCR) signals for their survival and growth. Besides the Immunoglobulin M (IgM) BCR, lymphoma cells can also express non–IgM (IgG) BCRs; however, the role of IgG BCRs in malignant B cell is not well understood. Here, we report poorer disease outcomes in diffuse large B cell lymphoma (DLBCL) expressing high IgM versus those expressing IgG1. Using isogenic lymphoma cells expressing distinct BCRs, we found that IgM expressing cells strongly outcompete their IgG1 counterparts. Mechanistically, IgG1 BCR is associated with a dysfunctional mitochondrial state and reduced cell survival. We show that mitochondrial dysfunction is triggered by accentuated calcium responses downstream of IgG1 BCR. Genetic reversal of IgG1 to IgM, pharmacological dampening of calcium signaling, or treatment with interleukin-21 can correct mitochondrial defects and rescue IgG1 survival. Our findings demonstrate that distinct BCR isotypes are inherently unique and can differentially affect B cell lymphoma pathogenesis.
No takes yet. Share an insight, caveat, or question.
Southern et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: